Laboratory of Translational Imaging in Oncology (LITO)
Part of the team (New biomarkers for phenotypic imaging) is dedicated to the design and/or evaluation of innovative radiotracers for molecular imaging by Positron Emission Tomography (PET), targeting key processes in cancerology. The objective is twofold: to better understand the mechanisms underlying the development of cancer and response or resistance to treatment, and to optimise therapeutic management through the identification of phenotypes that facilitate personalised medicine.
The other part (Integrated Radiomics for Precision Medicine) exploits PET imaging biomarkers, but also CT and MRI, and combines them with other biomarkers (clinical, pathological, blood, genomic) to establish a specific disease profile with prognostic or predictive value. The models developed should also improve our understanding of the processes associated with cancer.
-
-
-
Longitudinal mouse-PET imaging: a reliable method for estimating binding parameters without a reference region or blood samplingEuropean Journal of Nuclear Medicine and Molecular Imaging
-
18F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of OutcomeJournal of Nuclear Medicine
-
-
The Dark Side of Radiomics: On the Paramount Importance of Publishing Negative ResultsJournal of Nuclear Medicine
-
Triple negative breast cancer: imaging to provide better care for patientsPhysicians and researchers from Institut Curie have demonstrated the utility of FDG (Fluorodeoxyglucose) PET imaging to anticipate the effects of neoadjuvant treatment in triple negative breast cancer. This study was published in the European Journal of Nuclear Medicine and Molecular Imaging on August 22, 2023.10/11/2023 -
L’Institut Curie engagé sur le front des cancers masculinsEn novembre, mois de sensibilisation aux cancers masculins, l’Institut Curie met en lumière les spécificités de ces cancers. Ses trois sites, Paris, Saint-Cloud et Orsay, offrent à chaque patient une prise en charge optimale des cancers de la prostate, des testicules et du pénis, ainsi qu’un accès à l’innovation. Côté recherche, les équipes s’intéressent aux aspects biologiques et physiologiques de ces maladies.03/11/2023 -
Irène Buvat lauréate du prix Ruban Rose Avenir 2021La chercheuse de l’Institut Curie est récompensée pour ses travaux très innovants associant imagerie et intelligence artificielle dans la détection précoce des métastases de cancer du sein.06/10/2021